Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 4 Interventional

A Randomized, Double-blind, Placebo Controlled Comparison of Telmisartan Hydrochlorothiazide (HCT) and Valsartan HCT in Hypertension (HTN) Stage I/II Patients

ClinicalTrials.gov ID: NCT00240448

Public ClinicalTrials.gov record NCT00240448. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 6:47 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomised, Double-blind, Double-dummy, Placebo-controlled, Forced-titration, Comparison of MICARDIS® HCT (Telmisartan 80 mg / Hydrochlorothiazide 25 mg) Versus DIOVAN® HCT (Valsartan 160 mg / Hydrochlorothiazide 25 mg) Using Seated Trough Cuff Blood Pressure in Patients With Stage 1 and Stage 2 Hypertension

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The primary objective of this study is to compare the effectiveness of telmisartan 80 mg/hydrochlorothiazide 25 mg \[Micardis HCT\] to valsartan 160 mg/hydrochlorothiazide 25 mg \[Diovan HCT\] and placebo in the treatment of Stage 1 and Stage 2 hypertension.

Study identification

NCT ID
NCT00240448
Recruitment status
Completed
Study type
Interventional
Phase
Phase 4
Lead sponsor
Boehringer Ingelheim
Industry
Enrollment
1,109 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Sep 2003 (Type not available)
Primary completion
Jun 2004 (Actual)
Completion
Not listed
Last update posted
Nov 5, 2013

Started 2003

United States locations

U.S. sites
100
U.S. states
36
U.S. cities
93
Facility City State ZIP Site status
Boehringer Ingelheim Investigational Site Birmingham Alabama — —
Boehringer Ingelheim Investigational Site Huntsville Alabama — —
Boehringer Ingelheim Investigational Site Mobile Alabama — —
Boehringer Ingelheim Investigational Site Sctoosdale Arizona — —
Boehringer Ingelheim Investigational Site Tucson Arizona — —
Boehringer Ingelheim Investigational Site Bentonville Arkansas — —
Boehringer Ingelheim Investigational Site Carlisle Arkansas — —
Boehringer Ingelheim Investigational Site Hot Springs Arkansas — —
Boehringer Ingelheim Investigational Site Concord California — —
Memorial Research Medical Clinic Long Beach California — —
Boehringer Ingelheim Investigational Site Orange California — —
Boehringer Ingelheim Investigational Site Riverside California — —
Clinical Trials Research Roseville California — —
Boehringer Ingelheim Investigational Site Sacramento California — —
Boehringer Ingelheim Investigational Site San Leandro California — —
Boehringer Ingelheim Investigational Site Santa Ana California — —
Boehringer Ingelheim Investigational Site Sepulveda California — —
Boehringer Ingelheim Investigational Site Spring Valley California — —
Boehringer Ingelheim Investigational Site Torrance California — —
Boehringer Ingelheim Investigational Site Boulder Colorado — —
Boehringer Ingelheim Investigational Site Bridgeport Connecticut — —
Boehringer Ingelheim Investigational Site Farmington Connecticut — —
Clinical Research Consultants, Inc. Trumbull Connecticut — —
Boehringer Ingelheim Investigational Site Waterbury Connecticut — —
Boehringer Ingelheim Investigational Site Newark Delaware — —
Boehringer Ingelheim Investigational Site Coral Gables Florida — —
Boehringer Ingelheim Investigational Site Fort Lauderdale Florida — —
Boehringer Ingelheim Investigational Site Fort Myers Florida — —
Boehringer Ingelheim Investigational Site Holiday Florida — —
Boehringer Ingelheim Investigational Site Hollywood Florida — —
Christopher Chappel, MD Kissimmee Florida — —
Boehringer Ingelheim Investigational Site Largo Florida — —
Orlando Clinical Research Center Orlando Florida — —
Boehringer Ingelheim Investigational Site Palm Harbor Florida — —
Boehringer Ingelheim Investigational Site Panama City Florida — —
Attention: Larry I. Gilderman, D.O. Pembroke Pines Florida — —
Boehringer Ingelheim Investigational Site Pembroke Pines Florida — —
Boehringer Ingelheim Investigational Site Atlanta Georgia — —
Grady Memorial Hospital Atlanta Georgia — —
Boehringer Ingelheim Investigational Site Conyers Georgia — —
Treasure Valley Cardiology Boise Idaho — —
Boehringer Ingelheim Investigational Site Chicago Illinois — —
Cedar-Crosse Research Center Chicago Illinois — —
Herron Medical Center, Ltd. Chicago Illinois — —
Boehringer Ingelheim Investigational Site Orland Park Illinois — —
N Touch Research Peoria Illinois — —
Midwest Institute for Clinical Research Inc. Indianapolis Indiana — —
Boehringer Ingelheim Investigational Site Waterloo Iowa — —
Boehringer Ingelheim Investigational Site Shawnee Kansas — —
Boehringer Ingelheim Investigational Site Wichita Kansas — —
Boehringer Ingelheim Investigational Site Louisville Kentucky — —
Attn:William Smith New Orleans Louisiana — —
Boehringer Ingelheim Investigational Site Baltimore Maryland — —
Boehringer Ingelheim Investigational Site Brookline Massachusetts — —
Waltham Hospital Waltham Massachusetts — —
Boehringer Ingelheim Investigational Site Troy Michigan — —
Boehringer Ingelheim Investigational Site Brooklyn Center Minnesota — —
Radiant Research Edina Minnesota — —
Boehringer Ingelheim Investigational Site Jackson Mississippi — —
Boehringer Ingelheim Investigational Site Kansas City Missouri — —
Department of Medicine Camden New Jersey — —
Boehringer Ingelheim Investigational Site Cherry Hill New Jersey — —
Boehringer Ingelheim Investigational Site Kingston New York — —
Northport VAMC - Medical Service (111) Northport New York — —
Boehringer Ingelheim Investigational Site Rochester New York — —
Boehringer Ingelheim Investigational Site Scarsdale New York — —
Boehringer Ingelheim Investigational Site The Bronx New York — —
Boehringer Ingelheim Investigational Site Burlington North Carolina — —
Boehringer Ingelheim Investigational Site Cary North Carolina — —
Boehringer Ingelheim Investigational Site Durham North Carolina — —
Boehringer Ingelheim Investigational Site Raleigh North Carolina — —
Boehringer Ingelheim Investigational Site Stateville North Carolina — —
Boehringer Ingelheim Investigational Site Winston-Salem North Carolina — —
Boehringer Ingelheim Investigational Site Cincinnati Ohio — —
Radiant Reseach Cincinnati Ohio — —
Boehringer Ingelheim Investigational Site Columbus Ohio — —
Ohio State University Columbus Ohio — —
Radiant Research Columbus Ohio — —
Boehringer Ingelheim Investigational Site Mansfield Ohio — —
Boehringer Ingelheim Investigational Site Mogadore Ohio — —
Boehringer Ingelheim Investigational Site Oklahoma City Oklahoma — —
Boehringer Ingelheim Investigational Site Tulsa Oklahoma — —
Bock Clinical Research Collegeville Pennsylvania — —
Boehringer Ingelheim Investigational Site Philadelphia Pennsylvania — —
Boehringer Ingelheim Investigational Site Pottstown Pennsylvania — —
Boehringer Ingelheim Investigational Site East Providence Rhode Island — —
Boehringer Ingelheim Investigational Site Greer South Carolina — —
Boehringer Ingelheim Investigational Site Nashville Tennessee — —
Boehringer Ingelheim Investigational Site Austin Texas — —
Boehringer Ingelheim Investigational Site Carrollton Texas — —
Boehringer Ingelheim Investigational Site Dallas Texas — —
Boehringer Ingelheim Investigational Site Houston Texas — —
Boehringer Ingelheim Investigational Site McKinney Texas — —
Boehringer Ingelheim Investigational Site San Antonio Texas — —
Boehringer Ingelheim Investigational Site Salt Lake City Utah — —
Clinical Research Center of N. VA Falls Church Virginia — —
Boehringer Ingelheim Investigational Site Lacey Washington — —
Boehringer Ingelheim Investigational Site Lakewood Washington — —
Boehringer Ingelheim Investigational Site Madison Wisconsin — —
Boehringer Ingelheim Investigational Site Milwaukee Wisconsin — —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00240448, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Nov 5, 2013 · Synced Oct 22, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT00240448 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →